VoICE Immunization Evidence: Cost effectiveness
A multi-site study of cholera vaccination programs found that the vaccine was cost-effective in school- and community-based vaccination programs for children in India, Mozambique, and Indonesia.
Jeuland, M., Cook, J., Poulos, C., et al 2009. Cost-effectiveness of new-generation oral cholera vaccines: A multisite analysis. Value Health. 12:899–908.
PCV7 use in Argentina resulted in an estimated cost of US$5,599 per life year gained and the purchase of the 4 doses of vaccine for the entire cohort at a cost of US$26.5 dose would require an investment of US$73,823,806.
Giglio, N.D., Cane, A.D., Micone, P., et al 2010. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine. 28:2302–2310.
Assuming 90% coverage, a program in The Gambia using a 9-valent PCV (PCV9) would prevent approximately 630 hospitalizations, 40 deaths, and 1,000 DALYs over the first 5 years of life of a birth cohort. The estimated cost would be US$670 per DALY averted in The Gambia.
Kim, S., Lee, G. and Goldie, S. 2010. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. BMC Infectious Diseases. 10:260.
In Argentina, universal vaccination for Hepatitis A in children, at 95% vaccine coverage, can prevent over 350,000 hepatitis A infections per year and 428 deaths. Benefits persist at coverage rates as low as 70% with over 290,000 prevented infections. At 95% coverage rates, this program would save almost $24,000 annually.
Lopez, E., Debbag, R., Coudeville, L., et al 2007. The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis. Journal of Gastroenterology. 42:152–160.